

AMENDMENT TO RULES COMMITTEE PRINT 117-

54

OFFERED BY MR. CRENSHAW OF TEXAS

Add at the end of subtitle D of title VII the following new section:

1 **SEC. 7___ . GRANT PROGRAM TO STUDY TREATMENT OF**
2 **POST-TRAUMATIC STRESS DISORDER USING**
3 **CERTAIN PSYCHEDELIC SUBSTANCES.**

4 (a) GRANT PROGRAM.—The Secretary of Defense
5 shall carry out a program to award grants to eligible enti-
6 ties to conduct research on the treatment of members of
7 the Armed Forces serving on active duty with post-trau-
8 matic stress disorder using covered psychedelic sub-
9 stances.

10 (b) CRITERION FOR APPROVAL.—The Secretary may
11 award a grant under this section to an eligible entity to
12 conduct research if the Secretary determines that the re-
13 search involves a therapy that has the potential to dem-
14 onstrate significant medical evidence of a therapeutic ad-
15 vantage.

16 (c) ELIGIBLE ENTITIES.—The Secretary may award
17 a grant under this section to any of the following:

1 (1) A department or agency of the Federal Gov-
2 ernment or a State government.

3 (2) An academic institution.

4 (3) A nonprofit entity.

5 (d) USE OF GRANT FUNDS.—A recipient of a grant
6 awarded under this section may use the grant to—

7 (1) conduct one or more phase two clinical
8 trials for the treatment of post-traumatic stress dis-
9 order that—

10 (A) include members of the Armed Forces
11 serving on active duty as participants in the
12 clinical trial; and

13 (B) use individual or group therapy as-
14 sisted by covered psychedelic substances; or

15 (2) train practitioners to provide treatment to
16 members of the Armed Forces serving on active duty
17 for post-traumatic stress disorder using covered psy-
18 chedelic substances.

19 (e) PARTICIPATION IN CLINICAL TRIALS.—The Sec-
20 retary may authorize a member of the Armed Forces to
21 participate in a clinical trial that is conducted using a
22 grant awarded under this section or funds provided under
23 subsection (f) and is authorized pursuant to section 505
24 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
25 355), without regard to—

1 (1) whether the clinical trial involves a sub-
2 stance included in the schedule under section 202 of
3 the Controlled Substances Act (21 U.S.C. 812); or

4 (2) section 912a of title 10, United States Code
5 (article 112a of the Uniform Code of Military Jus-
6 tice).

7 (f) ADDITIONAL AUTHORITY.—In addition to award-
8 ing grants under this section, the Secretary may provide
9 funds for a clinical research trial using covered psychedelic
10 substances that is authorized pursuant to section 505 of
11 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
12 355) and includes members of the Armed Forces as par-
13 ticipants in the trial.

14 (g) DEFINITIONS.—In this section:

15 (1) The term “covered psychedelic substances”
16 means any of the following:

17 (A) 3,4-methylenedioxy-methamphetamine
18 (commonly known as “MDMA”).

19 (B) Psilocybin.

20 (C) Ibogaine.

21 (D) 5-Methoxy-N,N-dimethyltryptamine
22 (commonly known as “5-MeO-DMT”).

23 (2) The term “State” includes any State, dis-
24 trict, territory, or possession of the United States.

